I’m a pharmacist by training and, after many years and launches in the pharmaceutical industry, the thing that inspires me most is being a patient advocate. When I joined ACADIA, I found a company that shared this same passion for the patient. In every encounter and conversation I have with folks at ACADIA, I sense this purpose. Today my job is to grow awareness of Parkinson’s disease psychosis in the payer community and ultimately will be to make sure our drugs, if approved, are covered and reimbursed by payers. I’m helping ACADIA build out the organization and achieve our dream to serve the many patients suffering from Parkinson’s disease psychosis. I am proud to represent ACADIA and to bring this message to payers and other stakeholders managing health.
Senior Director, Biosciences
I joined ACADIA at its inception, when it was a small start-up organization. Our mission then was to use modern molecular techniques to make drugs with greatly improved efficacy, safety and tolerability compared to available drugs to better serve patients suffering from neuropsychiatric disorders. I was involved in the research that led to the discovery of NUPLAZID™, our proprietary, selective 5-HT2A serotonin receptor inverse agonist that is being developed as a novel treatment for Parkinson’s disease psychosis. We have undergone the ups and downs many biotech companies experience, but we have made tremendous progress and remained focused on our original goals. I am excited about the future and I look forward to the next phase of ACADIA’s development.